Key Insights

Highlights

Success Rate

89% trial completion (above average)

Treatment Research

20 treatments under study, led by Dronabinol

Published Results

22 trials with published results (21%)

Research Leaders

20 sponsors active, led by National Institute on Drug Abuse (NIDA)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

4.9%

5 terminated out of 103 trials

Success Rate

89.4%

+2.8% vs benchmark

Late-Stage Pipeline

8%

8 trials in Phase 3/4

Results Transparency

52%

22 of 42 completed with results

Key Signals

22 with results89% success

Data Visualizations

Phase Distribution

97Total
Not Applicable (43)
Early Phase 1 (6)
Phase 1 (9)
Phase 1/2 (4)
Phase 2 (24)
Phase 2/3 (3)
Phase 3 (2)
Phase 4 (6)

Trial Status

Completed42
Recruiting31
Not Yet Recruiting11
Unknown7
Terminated5
Active Not Recruiting3

Trial Success Rate

89.4%

Benchmark: 86.6%

Based on 42 completed trials

Clinical Trials (103)

Showing 20 of 20 trials
NCT06430580Early Phase 1CompletedPrimary

Cannabinoids and Biological Reactivity to Stress

NCT06891235Recruiting

Study of an Oral Fluid Testing Approach

NCT06085222Not ApplicableActive Not RecruitingPrimary

Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users

NCT07879612Phase 2Not Yet RecruitingPrimary

Semaglutide for the Treatment of Cannabis Use Disorder

NCT03995121Active Not Recruiting

SV2 PET Imaging With [11C]APP311

NCT07265752Phase 2Not Yet RecruitingPrimary

Tirzepatide for the Treatment of Cannabis Use Disorder

NCT07225777Phase 2TerminatedPrimary

Sex Differences in Neurobehavioral Response to THC

NCT07815691Phase 2RecruitingPrimary

Endocannabinoids in Reward

NCT07838311Phase 4Not Yet Recruiting

Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder

NCT07802990Phase 1/2Not Yet RecruitingPrimary

Lemborexant for Cannabis Use Disorder

NCT07468552Phase 2Not Yet RecruitingPrimary

Trial of Tirzepatide for the Treatment of Cannabis Use Disorder

NCT04517474Not ApplicableCompletedPrimary

Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use.

NCT05445180Not ApplicableRecruiting

Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use

NCT05522205Not ApplicableActive Not RecruitingPrimary

Regulated Cannabis Access in Basel

NCT06058702Phase 1Recruiting

Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans

NCT07787572Not ApplicableNot Yet RecruitingPrimary

Applying Neuromodulation to Boost the Efficacy of Motivational Interviewing

NCT06661031Not ApplicableEnrolling By InvitationPrimary

Developing a Telehealth + mHealth Cannabis Use Intervention for Young Adults

NCT06920238Phase 1CompletedPrimary

Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use

NCT07685964Phase 1/2Not Yet RecruitingPrimary

Pregnenolone for Cannabis Use Disorder and Depression

NCT06584942Phase 4Completed

Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)

Scroll to load more

Research Network

Common Treatments

  • Dronabinol6
  • Contingency Management4
  • Repetitive Transcranial Magnetic Stimulation Rtms3
  • Cannabidiol3
  • Varenicline3

Active Sponsors

  • National Institute on Drug Abuse (NIDA)49
  • Medical University of South Carolina12
  • Yale University7
  • Centre for Addiction and Mental Health7
  • Massachusetts General Hospital6

Top Investigators

Related Conditions

  • Cannabis Dependence9
  • Cannabis Use6
  • Schizophrenia5
  • Cannabis Abuse5
  • Alcohol Use Disorder5

Activity Timeline